Make Informed Investment Decisions with Affordable Access to Experts
A detailed look at JNJ’s Esketamine Nasal spray in treatment resistant depression post FDA approvalTicker(s): JNJ, LLY
Name: Dr Samuel Wilkinson - MD
Institution: Yale University
- Assistant Professor at Yale School of Medicine and Assistant Director of the Yale Depression Research Program.
- Treats roughly 60 TRD patients per month, in a mix of settings including clinical practice and clinical trials; manages a growing ketamine service at Yale, which provides about 15-25 treatments per week.
- Served as PI or co-investigator on at least 12 clinical trials involving depression therapeutics including a large, federally funded trial comparing ECT and IV ketamine; runs a busy clinical service (the Yale Interventional Psychiatry Service), which offers electroconvulsive therapy, ketamine, and transcranial magnetic stimulation to patients.
Please tell us about your professional/clinical experience. How do you currently treat a patient?Added By: joe_mccann
What is the abuse potential of the drugs you’re currently prescribing, vs esketamine? Would that affect your choice or your patient’s?Added By: joe_mccann
How concerned are you about the increased risk of sedation, dissociation and higher blood pressure observed in the study for esketamine?Added By: joe_mccann
The staff report noted there were six deaths among patients taking the J&J drug, of which three were suicide in the esketamine depression program. However, consensus was that it’s unrelated to the drug. How does this compare to other trials in depression, to your knowledge?Added By: joe_mccann
On a scale of 1-10, how excited are you for esketamine?Added By: joe_mccann
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.